遅発性ポンペ病遺伝子治療薬の安全性と有効性の評価
遅発性ポンペ病患者におけるヒト酸α-グルコシダーゼ(GAA)導入遺伝子を発現するアデノ随伴ウイルスベクターの静脈内注射の安全性、忍容性、および有効性を評価するための多中心、シングルアーム、非標識の研究
This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease. Patients diagnosed with late-onset Pompe disease (LOPD) who are ≥ 6 years old will be studied.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:GeneCradle, Inc China
- 電話番号:86-13501380583
- メール:ind@bj-genecradle.com
研究場所
-
-
-
Beijing、中国、100853
- 募集
- Chinese PLA General Hospital
-
主任研究者:
- Guang Yang
-
コンタクト:
- Xinting Liu
- 電話番号:16601558283
- メール:lxting0531@163.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥ 6 years, males or females;
- Patient has a diagnosis of LOPD;
- Patient has upright FVC ≥ 30% of predicted normal value;
- A 6MWT ≥ 40 meters, assistive device allowed;
- The patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed.
Exclusion Criteria:
- Patient who has any history or concurrent clinical organic disease, including cardiovascular and liver diseases, respiratory system, nervous system disease, or any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.
- Patient who requires invasive mechanical ventilation, or rely on noninvasive non-non-invasive assisted ventilation when sitting upright;
- Patient who is positive for human immunodeficiency (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody;
- Patient with a history of glucocorticoid allergy;
- Patient who has a contraindication to study drug or to corticosteroids, or has demonstrated hypersensitivity to any of the components of the study drug;
- Patient who has AAV9 neutralizing antibody titer ≥ 1:100;
- Patient who has participated in a previous gene therapy research trial;
- Pregnant or lactating female participants;
- Patients who have fertility plans within 6 months from screening to the end of the study and are unwilling to take effective physical contraceptive measures (such as a condom, intrauterine device, contraceptive ring, ligation, abstinence, etc.) for contraception (including the subject's partner);
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Low dosage group
Single intravenous administration of GC301 at a dose of 3.0 x 10^13 vector genomes per kilogram body weight |
GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene |
|
実験的:High dosage group
Single intravenous administration of GC301 at a dose of 6.0 x 10^13 vector genomes per kilogram body weight |
GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
プロトコル固有の有害事象に基づく用量制限毒性 (DLT) 率 (フェーズ 1)
時間枠:治療後30日以内
|
治療後30日以内
|
|
|
Number of Participants With Adverse Events
時間枠:52 weeks
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability |
52 weeks
|
|
Percent Predicted Upright Forced Vital Capacity (FVC)(Phase 2)
時間枠:52 weeks
|
Change from baseline in percentage of predicted FVC measured by pulmonary function testing |
52 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
AAVキャプシドおよびGAA導入遺伝子に対する免疫応答の発生
時間枠:52週間
|
52週間
|
|
|
6-Minute Walk Test
時間枠:52 weeks
|
Change from baseline in the distance walked in the 6 minute walk test (6MWT), which is a standardized assessment of how far an individual can walk on a hard, flat surface in a period of 6 minutes |
52 weeks
|
|
Maximum Inspiratory Pressure (MIP)
時間枠:52 weeks
|
Change from baseline in MIP measured by pulmonary function testing |
52 weeks
|
|
Maximum Expiratory Pressure (MEP)
時間枠:52 weeks
|
Change from baseline in MEP measured by pulmonary function testing |
52 weeks
|
|
Muscle Status Testing - Quick Motor Function Test (QMFT) Measure
時間枠:52 weeks
|
Measurement of functional motor abilities using the Quick Motor Function Test (QMFT) will be performed and the results compared with baseline. |
52 weeks
|
|
Quality of life evaluation: 12-item short form health survey (SF-12) for LOPD participants
時間枠:52 weeks
|
SF-12, a 12 item-questionnaire, used to assess health-related quality of life in participants aged >=18 years at screening/baseline. SF-12 consisted of 12 items, which were categorized into eight domains (subscales) of functioning and well-being: physical functioning, role-physical, role emotional, mental health, bodily pain, general health, vitality and social functioning, with each domain score ranged from 0 (poor health) to 100 (better health), higher scores indicated good health condition. These eight domains were further summarized into 2 summary scores, physical component summary (PCS) and mental component summary (MCS). The score range for each of these 2 summary scores was from 0 (poor health) to 100 (better health), higher scores indicated a better health-related quality of life. |
52 weeks
|
|
Time needed for non-invasive ventilatory support
時間枠:52 weeks
|
Change from baseline in time duration that needed for non-invasive ventilatory support |
52 weeks
|
|
The viral load of adeno-associated virus (AAV) vector
時間枠:52 weeks
|
To assess the change of AAV vector copy numbers within 52 weeks after administration. |
52 weeks
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
GAA enzymatic activity
時間枠:52 weeks
|
Change from baseline in GAA enzymatic activity in muscle biopsies |
52 weeks
|
|
GAA enzymatic activity
時間枠:52 weeks
|
Change from baseline in GAA enzymatic activity in blood |
52 weeks
|
|
Glycogen content in muscle
時間枠:52 weeks
|
Change from baseline in glycogen content in muscle biopsies |
52 weeks
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Guang Yang、Chinese PLA General Hospital
- 主任研究者:Guang Yang、Chinese PLA General Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- JLJY-GC301-LOPD-001
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。